These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

315 related articles for article (PubMed ID: 26273573)

  • 21. New developments in vaccine research--unveiling the secret of vaccine adjuvants.
    de Veer M; Meeusen E
    Discov Med; 2011 Sep; 12(64):195-204. PubMed ID: 21955847
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Examination of the effects of virus inactivation methods on the induction of antibody- and cell-mediated immune responses against whole inactivated H9N2 avian influenza virus vaccines in chickens.
    Astill J; Alkie T; Yitbarek A; Taha-Abdelaziz K; Bavananthasivam J; Nagy É; Petrik JJ; Sharif S
    Vaccine; 2018 Jun; 36(27):3908-3916. PubMed ID: 29853199
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Tomorrow's vector vaccines for small ruminants.
    Kyriakis CS
    Vet Microbiol; 2015 Dec; 181(1-2):47-52. PubMed ID: 26297534
    [TBL] [Abstract][Full Text] [Related]  

  • 24. HIV gp120 vaccine - VaxGen: AIDSVAX, AIDSVAX B/B, AIDSVAX B/E, HIV gp120 vaccine - Genentech, HIV gp120 vaccine AIDSVAX - VaxGen, HIV vaccine AIDSVAX - VaxGen.
    Adis International Ltd
    Drugs R D; 2003; 4(4):249-53. PubMed ID: 12848591
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Recent advances of vaccine adjuvants for infectious diseases.
    Lee S; Nguyen MT
    Immune Netw; 2015 Apr; 15(2):51-7. PubMed ID: 25922593
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Herpes simplex virus vaccine studies: from past to present].
    Us D
    Mikrobiyol Bul; 2006 Oct; 40(4):413-33. PubMed ID: 17205702
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The impact of new technologies on vaccine development.
    Winther MD; Dougan G
    Biotechnol Genet Eng Rev; 1984; 2():1-39. PubMed ID: 6085856
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Biotechnology approaches to produce potent, self-adjuvanting antigen-adjuvant fusion protein subunit vaccines.
    Moyle PM
    Biotechnol Adv; 2017; 35(3):375-389. PubMed ID: 28288861
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Development and clinical application of new polyvalent combined paediatric vaccines.
    André FE
    Vaccine; 1999 Mar; 17(13-14):1620-7. PubMed ID: 10194814
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Idiotypic vaccination for B-cell malignancies as a model for therapeutic cancer vaccines: from prototype protein to second generation vaccines.
    Ruffini PA; Neelapu SS; Kwak LW; Biragyn A
    Haematologica; 2002 Sep; 87(9):989-1001. PubMed ID: 12217812
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Polio endgame: Lessons for the global rotavirus vaccination program.
    Jiang B; Patel M; Glass RI
    Vaccine; 2019 May; 37(23):3040-3049. PubMed ID: 31027927
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Update on antiviral DNA vaccine research (1998-2000).
    Schultz J; Dollenmaier G; Mölling K
    Intervirology; 2000; 43(4-6):197-217. PubMed ID: 11251376
    [TBL] [Abstract][Full Text] [Related]  

  • 33. mRNA as a Transformative Technology for Vaccine Development to Control Infectious Diseases.
    Maruggi G; Zhang C; Li J; Ulmer JB; Yu D
    Mol Ther; 2019 Apr; 27(4):757-772. PubMed ID: 30803823
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Development of Protective Immunity against Inactivated Iranian Isolate of Foot-and-Mouth Disease Virus Type O/IRN/2007 Using Gamma Ray-Irradiated Vaccine on BALB/c Mice and Guinea Pigs.
    Motamedi-Sedeh F; Soleimanjahi H; Jalilian AR; Mahravani H; Shafaee K; Sotoodeh M; Taherkarami H; Jairani F
    Intervirology; 2015; 58(3):190-6. PubMed ID: 26202581
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Gene-based vaccines: recent technical and clinical advances.
    Ulmer JB; Wahren B; Liu MA
    Trends Mol Med; 2006 May; 12(5):216-22. PubMed ID: 16621717
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Feasible improvements in vaccines in the Expanded Programme on Immunization.
    McIntosh K
    Rev Infect Dis; 1989; 11 Suppl 3():S530-7. PubMed ID: 2669097
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Production of recombinant subunit vaccines: protein immunogens, live delivery systems and nucleic acid vaccines.
    Liljeqvist S; Ståhl S
    J Biotechnol; 1999 Jul; 73(1):1-33. PubMed ID: 10483112
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Advancing Homogeneous Antimicrobial Glycoconjugate Vaccines.
    Adamo R
    Acc Chem Res; 2017 May; 50(5):1270-1279. PubMed ID: 28463499
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Emerging Technologies for Low-Cost, Rapid Vaccine Manufacture.
    Kis Z; Shattock R; Shah N; Kontoravdi C
    Biotechnol J; 2019 Jan; 14(1):e1800376. PubMed ID: 30537361
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Polyester as Antigen Carrier toward Particulate Vaccines.
    Gonzalez-Miro M; Chen S; Gonzaga ZJ; Evert B; Wibowo D; Rehm BHA
    Biomacromolecules; 2019 Sep; 20(9):3213-3232. PubMed ID: 31122016
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.